Division of Gastroenterology and Hepatology, UNC Liver Center, The University of North Carolina at Chapel Hill, 8004 Burnett Womack, CB #7584, Chapel Hill, NC, 27599-7584, USA.
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
Dig Dis Sci. 2019 Jun;64(6):1460-1469. doi: 10.1007/s10620-019-5471-7. Epub 2019 Jan 23.
Inpatient charges for patients with cirrhosis are substantial. We aimed to examine trends in inpatient charges among patients with cirrhosis to determine the drivers of healthcare expenditures. We hypothesized that alcoholic cirrhosis (AC) was a significant contributor to overall expense.
We performed a retrospective analysis of the Health Care Utilization Project Nationwide Inpatient Sample Database 2002-2014 (annual cross-sectional data) and New York and Florida State Inpatient Databases 2010-2012 (longitudinal data). Adult patients with cirrhosis of the liver were categorized as AC versus all other etiologies of cirrhosis combined. Patient characteristics were analyzed using ordinary least squares regression modeling. A random effects model was used to evaluate 30-day readmissions.
In total, 1,240,152 patients with cirrhosis were admitted between 2002 and 2014. Of these, 567,510 (45.8%) had a diagnosis of AC. Total charges for AC increased by 95.7% over the time period, accounting for 59.9% of all inpatient cirrhosis-related charges in 2014. Total aggregate charges for AC admissions were $28 billion and increased from $1.4B in 2002 to $2.8B by 2014. In the NIS and SID, patients with AC were younger, white and male. Readmission rates at 30, 60, and 90 days were all higher among AC patients.
Inpatient charges for cirrhosis care are high and increasing. Alcohol-related liver disease accounts for more than half of these charges and is driven by sheer volume of admissions and readmissions of the same patients. Effective alcohol addictions therapy may be the most cost-effective way to substantially reduce inpatient cirrhosis care expenditures.
肝硬化患者的住院费用很高。我们旨在研究肝硬化患者住院费用的趋势,以确定医疗支出的驱动因素。我们假设酒精性肝硬化(AC)是总费用的重要贡献因素。
我们对 2002-2014 年卫生保健利用项目全国住院患者样本数据库(年度横截面数据)和 2010-2012 年纽约和佛罗里达州住院患者数据库(纵向数据)进行了回顾性分析。将患有肝硬化的成年患者分为 AC 与所有其他病因的肝硬化。使用普通最小二乘法回归模型分析患者特征。使用随机效应模型评估 30 天再入院率。
共有 1240152 名肝硬化患者在 2002 年至 2014 年期间住院。其中 567510 名(45.8%)诊断为 AC。在这段时间内,AC 的总费用增加了 95.7%,占 2014 年所有与肝硬化相关住院费用的 59.9%。AC 入院的总费用为 280 亿美元,从 2002 年的 14 亿美元增加到 2014 年的 280 亿美元。在 NIS 和 SID 中,AC 患者更年轻、更白、更男性化。AC 患者的 30、60 和 90 天再入院率均较高。
肝硬化治疗的住院费用很高且呈上升趋势。酒精相关肝病占这些费用的一半以上,其驱动因素是同一批患者的入院和再入院人数众多。有效的酒精成瘾治疗可能是降低肝硬化治疗住院费用的最具成本效益的方法。